Clinical trials: Patient Preference, open to volunteers
- Condition Patient Preference
- Status Open to volunteers
- Funder type Industry (pharma, biotech, devices)
Primary Immunodeficiencies (PID), Secondary Immunodeficiencies (SID)
Assessing Patient Preference for Infusion Systems
This crossover study evaluates patient experiences and preferences between mechanical and electrical infusion pumps for subcutaneous immunoglobulin (SCIg) therapy.
- Trial name
- NCT07189013
- Testing
- Mechanical infusion pump
- Where
- United Kingdom
- Volunteers
- 52 people
- Sponsor
- KORU Medical Systems, Inc.
Primary Immune Thrombocytopenia
A Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment
This study aims to evaluate treatment preferences of patients with Primary Immune Thrombocytopenia (ITP) in the United States (US) by conducting a preference elicitation survey.
- Trial name
- NCT07786077
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Diabete Mellitus, Type2diabetes
CGM Experience, Preferences & Blood Glucose Parameters
This is an open-label, prospective, multicenter observational study designed to evaluate the perceived benefits, device experience, preference, and glucose-related parameters associated with the Instara-1 Continuous Glucose…
- Conditions
- Diabete Mellitus, Type2diabetes, type1diabetes, Gestational Diabetes
- Trial name
- NCT07607015
- Testing
- CGM
- Volunteers
- 75 people
- Sponsor
- Getz Pharma
Haemophilia A
Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in Germany
This study aims to generate structured patient preference evidence on prophylactic treatment options for haemophilia A for adults with and without inhibitors to support health technology assessment and benefit evaluation…
- Trial name
- NCT07653139
- Testing
- No treatment given
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Novo Nordisk A/S
Non-Small Cell Lung Cancer
CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC
This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily…
- Trial name
- CHOICE (NCT07413757)
- Where
- China
- Volunteers
- 590 people
- Sponsor
- AstraZeneca